J Korean Ophthalmol Soc > Volume 59(5); 2018 > Article
Journal of the Korean Ophthalmological Society 2018;59(5):437-443.
DOI: https://doi.org/10.3341/jkos.2018.59.5.437    Published online May 15, 2018.
Intravitreal Aflibercept Monotherapy for Treating Submacular Hemorrhage Secondary to Neovascular Age-related Macular Degeneration.
Sue Hey Chae, Soh Eun Ahn, Hee Seong Yoon
Sungmo Eye Hospital, Busan, Korea. heesyoon@dreamwiz.com
삼출 나이관련황반변성에 의한 황반하출혈에서 유리체강내 애플리버셉트 단독요법의 임상적 효과
Correspondence:  Hee Seong Yoon,
Email: heesyoon@dreamwiz.com
Received: 28 December 2017   • Revised: 5 February 2018   • Accepted: 19 April 2018
To evaluate the effects of intravitreal aflibercept injection in the treatment of submacular hemorrhage secondary to neovascular age-related macular degeneration (nAMD). METHODS: This retrospective, observational study included patients diagnosed with nAMD with submacular hemorrhage treated with intravitreal aflibercept monotherapy. A total of 54 eyes of 54 patients were treated with an initial series of three monthly intravitreal aflibercept injections followed by as-needed injections. At the 6 month follow-up, changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and submacular hemorrhage area (SMH) were evaluated. RESULTS: The mean preoperative BCVA was 0.79 ± 0.59 logMAR, which improved significantly to 0.53 ± 0.46 logMAR at 3 months and 0.48 ± 0.50 logMAR at 6 months (p < 0.001, in both). The CMT significantly decreased in all eyes: preoperative, 454.4 ± 131.5 µm, to 242.6 ± 39.7 µm at 6 months. The SMH was also reduced in all eyes: preoperative, 6.4 ± 4.8 disc areas (DAs) to 0.8 ± 1.4 DAs at 6 months. Ten eyes were diagnosed with typical nAMD (18.5%) and 44 eyes were diagnosed polypoidal choroidal vasculopathy (81.5%). There was no significant difference at 6 months in the visual outcomes of the subgroups. CONCLUSIONS: Intravitreal aflibercept monotherapy is well-tolerated as a treatment in maintaining or improving vision in patients with SMH secondary to nAMD.
Key Words: Aflibercept;Central macular thickness;Neovascular age-related macular degeneration;Submacular hemorrhage

Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2022 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next